Generic Emerphed Availability
Last updated on Sep 11, 2024.
Emerphed is a brand name of ephedrine, approved by the FDA in the following formulation(s):
EMERPHED (ephedrine sulfate - solution;intravenous)
-
Manufacturer: NEXUS
Approval date: April 17, 2020
Strength(s): 50MG/10ML (5MG/ML) [RLD] -
Manufacturer: NEXUS
Approval date: February 28, 2023
Strength(s): 25MG/5ML (5MG/ML) [RLD]
Has a generic version of Emerphed been approved?
No. There is currently no therapeutically equivalent version of Emerphed available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Emerphed. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
Patent 11,090,278
Issued: August 17, 2021
Inventor(s): Ahmed Shahid
Assignee(s): Nexus Pharmaceuticals, Inc.The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same.
Patent expiration dates:
- May 16, 2040✓
- May 16, 2040
-
Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
Patent 11,241,400
Issued: February 8, 2022
Inventor(s): Ahmed Shahid
Assignee(s): Nexus Pharmaceuticals, Inc.The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same.
Patent expiration dates:
- May 16, 2040✓
- May 16, 2040
-
Patent 11,464,752
Patent expiration dates:
- May 16, 2040✓
- May 16, 2040
-
Patent 11,478,436
Patent expiration dates:
- May 16, 2040✓
- May 16, 2040
-
Patent 11,571,398
Patent expiration dates:
- May 16, 2040✓
- May 16, 2040
More about Emerphed (ephedrine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: vasopressors
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.